MARKET

RIGL

RIGL

Rigel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.780
+0.040
+1.07%
Pre Market: 3.550 -0.23 -6.08% 04:59 09/28 EDT
OPEN
3.770
PREV CLOSE
3.740
HIGH
3.810
LOW
3.720
VOLUME
100
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
2.270
MARKET CAP
645.81M
P/E (TTM)
-69.2308
1D
5D
1M
3M
1Y
5Y
Rigel to Participate in Three Upcoming Investor Conferences
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in ...
PR Newswire · 09/02 11:30
BRIEF-Rigel Pharmaceuticals Publishes Data From Phase 2 Trial Of Fostamatinib In Hospitalized Covid-19 Patients
reuters.com · 09/01 11:49
Data from NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In Hospitalized COVID-19 Patients Published In Clinical Infectious Diseases
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in
Benzinga · 09/01 11:31
Rigel Pharmaceuticals Granted U.S. Patent Titled 'ACVR2A-specific antibody and method of treatment of muscle atrophy'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5413&f=G&l=50&d=PTXT&p=109&S1=20210831&OS=20210831&RS=20210831
Benzinga · 08/31 13:52
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
Zacks.com · 08/18 15:47
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Zacks · 08/16 14:27
SoFi Technologies, Cricut, FIGS among premarket losers' pack
ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sierra...
Seekingalpha · 08/13 12:54
BRIEF-Rigel Pharmaceuticals Provides Update On Covid-19 Program
reuters.com · 08/13 12:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RIGL. Analyze the recent business situations of Rigel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RIGL stock price target is 8.33 with a high estimate of 11.00 and a low estimate of 7.00.
High11.00
Average8.33
Low7.00
Current 3.780
EPS
Actual
Estimate
-0.040.040.120.20
Q3 2020
Q4 2020
  • 0
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 216
Institutional Holdings: 157.20M
% Owned: 92.01%
Shares Outstanding: 170.85M
TypeInstitutionsShares
Increased
49
5.91M
New
22
6.99M
Decreased
47
13.11M
Sold Out
16
2.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Non-Executive Chairman/Independent Director
Gary Lyons
President/Chief Executive Officer/Director
Raul Rodriguez
Chief Financial Officer/Executive Vice President
Dean Schorno
Executive Vice President/General Counsel/Secretary
Dolly Vance
Executive Vice President
Wolfgang Dummer
Executive Vice President
David Santos
Director
Alison Hannah
Independent Director
Bradford Goodwin
Independent Director
Keith Katkin
Independent Director
Brian Kotzin
Independent Director
Gregg Lapointe
Independent Director
Walter Moos
Independent Director
Jane Wasman
No Data
  • All
  • Financials
  • Insiders
More
About RIGL
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.